1.15
-0.03 (-2.54%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | -10.42 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.84% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | -23.5% | ||
| PM (TTM) | -38.35% | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | -0.67 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.66 | ||
| Quick Ratio | 0.53 | ||
| Altman-Z | -8.31 |
ChartMill assigns a fundamental rating of 3 / 10 to NEOS.
ChartMill assigns a valuation rating of 0 / 10 to Neos Therapeutics (NEOS). This can be considered as Overvalued.
Neos Therapeutics (NEOS) has a profitability rating of 3 / 10.
The financial health rating of Neos Therapeutics (NEOS) is 2 / 10.
The dividend rating of Neos Therapeutics (NEOS) is 0 / 10 and the dividend payout ratio is 0%.